Current status and progress of concurrent chemoradiotherapy in patients with locally advanced non‐small cell lung cancer prior to the approval of durvalumab

Current status and progress of concurrent chemoradiotherapy in patients with locally advanced non‐small cell lung cancer prior to the approval of durvalumab

Background The standard treatment for patients with unresectable locally advanced (LA) non‐small cell lung cancer (NSCLC) is chemoradiotherapy (CRT). Consolidation therapy with durvalumab after CRT demonstrated survival benefits and was approved in Japan in July 2018. The use of immune checkpoint in...

Full description

Bibliographic Details
Main Authors: Tomoya Fukui, Shinji Hosotani, Itaru Soda, Takahiro Ozawa, Seiichiro Kusuhara, Mikiko I. Kakegawa, Masashi Kasajima, Yasuhiro Hiyoshi, Satoshi Igawa, Masanori Yokoba, Hisashi Mitsufuji, Masaru Kubota, Masato Katagiri, Jiichiro Sasaki, Hiromichi Ishiyama, Katsuhiko Naoki
Format: Article
Language:English
Published: Wiley 2020-04-01
Series:Thoracic Cancer
Subjects:
Chemoradiotherapy
immune checkpoint inhibitor
locally advanced
non‐small cell lung cancer
radiation pneumonitis
Online Access:https://doi.org/10.1111/1759-7714.13357

Internet

https://doi.org/10.1111/1759-7714.13357

Similar Items